相关实验视频

Updated: Jun 6, 2025

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

在患有阿尔茨海默氏症的患者中,皮层陶聚合模式与阿普拉克西亚有关

Gérard N Bischof¹, Elena Jaeger¹, Kathrin Giehl¹

¹From the Multimodal Neuroimaging Group, Department of Nuclear Medicine (G.N.B., E.J., K.G., A.D.), Department of Psychiatry (F.J.), Department of Neurology (O.A.O., E.K., P.H.W.), Medical Faculty and University Hospital of Cologne, University of Cologne; Molecular Organization of the Brain (G.N.B., A.D.), Institute for Neuroscience and Medicine II, Research Center Juelich; German Center for Neurodegenerative Diseases (F.J.), Bonn/Cologne, Germany; Institute for Translational Research (S.O.B.), and Department of Family Medicine (S.O.B.), Texas College of Osteopathic Medicine, University of North Texas Health Science Center, Fort Worth; and Cognitive Neuroscience (P.H.W.), Institute for Neuroscience and Medicine (INM-3), Research Center Juelich, Germany.

|December 3, 2024

概括

在特定的大脑区域积聚陶与阿尔茨海默氏症 (AD) 中的无力度严重程度有关. 这一发现可能会改善基于他们个人的tau病理学的AD患者的诊断和分类.

科学领域:

神经科学是一个神经科学.
神经学神经学
放射学放射学是指放射学

背景情况:

失调是阿尔茨海默病 (AD) 的常见症状,但其潜在原因尚未完全理解.
以前的研究表明,阿尔茨海默氏症的认知缺陷与特定大脑区域的陶沉积之间存在联系.

研究的目的:

调查与实践相关的大脑区域区域的区域性tau病理与阿尔茨海默病患者的非实践性缺陷之间的关联.
测试沉积的特定模式与阿普拉克西亚严重程度相关的假设.

主要方法:

招募了生物标志物确认的AD患者和认知不受损 (CU) 控制者.
使用痴呆症厌恶性查测试评估厌恶性.
使用tau标记器[18F]PI-2620进行PET成像,以量化tau病理.

主要成果:

在阿尔茨海默氏症患者中,在顶部,部和部区域的陶聚合和阿普拉克西亚严重程度之间发现了显著的相关性.
在运动或皮层下区域的摄取量与无动症之间没有发现显著的相关性.

结论:

参与实践的特定皮层区域的陶沉积可能会导致局部的神经元功能障碍,导致AD中实践表现的剂量依赖性下降.
了解这种关系可以提高AD患者的个体诊断特征和分类.

更多相关视频

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on ¹⁸F-AV-1451

Published on: April 18, 2025

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening

Published on: November 20, 2018

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...